News on in vitro diagnostics for gastrointestinal disease.
The multi-omics translational software developer is helping the Crohn's & Colitis Foundation validate its research into biomarkers that can predict complications requiring surgery.
The study will recruit up to 200 patients with active Crohn's disease or ulcerative colitis and sort them into high- and low-risk cohorts using the PredictSure IBD test.
Under the agreement, Theradiag will promote, license, and distribute PredictImmune's PredictSure IBD test in France, Belgium, Luxembourg, Switzerland, and the Maghreb countries.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
The firm, Phenomix Sciences, anticipates that its test will help drive adoption of medications for obesity at a time when patients are reluctant to take them.
